Literature DB >> 33919283

Antimicrobial Susceptibility Pattern of Salmonella spp. Isolated from Enteric Fever Patients in Nepal.

Anu Maharjan1, Binod Dhungel1, Anup Bastola2, Upendra Thapa Shrestha1, Nabaraj Adhikari1, Megha Raj Banjara1, Binod Lekhak1, Prakash Ghimire1, Komal Raj Rijal1.   

Abstract

INTRODUCTION: Enteric fever, a systemic infection caused by Salmonella enterica Typhi and S. enterica Paratyphi is one of the most common infections in developing countries such as Nepal. Aside from irrational practices of antibiotic use, mutations in chromosomal genes encoding DNA gyrase and Topoisomerase IV and by plasmid mediated quinolone resistant (PMQR) genes are suggested mechanisms for the development of resistance to nalidixic acid and reduced susceptibility to ciprofloxacin. Regardless of high endemicity of enteric fever in Nepal, there is paucity of studies on prevalence and drug-resistance of the pathogen. Therefore, this study aimed to assess the antibiotic susceptibility pattern of Salmonella isolates and determine the minimum inhibitory concentration of ciprofloxacin.
METHODS: A total of 1298 blood samples were obtained from patients with suspected enteric fever, attending Sukraraj Tropical and Infectious Disease Hospital (STIDH) during March-August, 2019. Blood samples were inoculated immediately into BACTEC culture bottles and further processed for isolation and identification of Salmonella Typhi and S. Paratyphi. Axenic cultures of the isolates were further subjected to antimicrobial susceptibility testing (AST) by using the modified Kirby-Bauer disc diffusion method based on the guidelines by CLSI. The minimum inhibitory concentration (MIC) of ciprofloxacin was determined by agar-dilution method.
RESULTS: Out of 1298 blood cultures, 40 (3.1%) were positive for Salmonella spp. among which 29 (72.5%) isolates were S. Typhi and 11 (27.5%) isolates were S. Paratyphi A. In AST, 12.5% (5/40), 15% (6/40) and 20% (8/40) of the Salmonella isolates were susceptible to nalidixic acid, ofloxacin and levofloxacin, respectively, whereas none of the isolates were susceptible to ciprofloxacin. The MIC value for ciprofloxacin ranged from 0.06-16 µg/mL in which, respectively, 5% (2/40) and 52.5% (21/40) of the isolates were susceptible and resistant to ciprofloxacin. None of the isolates showed multidrug-resistance (MDR) in this study.
CONCLUSION: This study showed high prevalence of quinolone-resistant Salmonella spp., while there was marked re-emergence of susceptibilities to traditional first option drugs. Hence, conventional first-line-drugs and third-generation cephalosporins may find potential usage as the empirical drugs for enteric fever. Although our reporting was free of MDR strains, extensive surveillance, augmentation of diagnostic facilities and treatment protocol aided by AST report are recommended for addressing the escalating drug-resistance in the country.

Entities:  

Keywords:  MIC; PMQR; S. enterica Paratyphi A; Salmonella enterica Typhi; blood culture; enteric fever

Year:  2021        PMID: 33919283     DOI: 10.3390/idr13020037

Source DB:  PubMed          Journal:  Infect Dis Rep        ISSN: 2036-7430


  52 in total

1.  Chloramphenicol-resistant typhoid fever in Vietnam associated with R factor.

Authors:  T Butler; N N Linh; K Arnold; M Pollack
Journal:  Lancet       Date:  1973-11-03       Impact factor: 79.321

Review 2.  Emergence of plasmid-mediated resistance to quinolones in Enterobacteriaceae.

Authors:  Patrice Nordmann; Laurent Poirel
Journal:  J Antimicrob Chemother       Date:  2005-07-14       Impact factor: 5.790

3.  Plasmid-mediated resistance to multiple antibiotics in Salmonella typhi.

Authors:  F W Goldstein; J C Chumpitaz; J M Guevara; B Papadopoulou; J F Acar; J F Vieu
Journal:  J Infect Dis       Date:  1986-02       Impact factor: 5.226

Review 4.  Plasmid-mediated quinolone resistance: a multifaceted threat.

Authors:  Jacob Strahilevitz; George A Jacoby; David C Hooper; Ari Robicsek
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

5.  Decreased susceptibility to fluoroquinolones and gyrA gene mutation in the Salmonella enterica serovar Typhi and Paratyphi A isolated in Katmandu, Nepal, in 2003.

Authors:  Toshiro Shirakawa; Bishnu Acharya; Shohiro Kinoshita; Shunichi Kumagai; Akinobu Gotoh; Masato Kawabata
Journal:  Diagn Microbiol Infect Dis       Date:  2006-02-08       Impact factor: 2.803

6.  Prevalence of Salmonella typhi and paratyphi infection in children: a hospital based study.

Authors:  B Prajapati; G K Rai; S K Rai; H C Upreti; M Thapa; G Singh; R M Shrestha
Journal:  Nepal Med Coll J       Date:  2008-12

7.  ACC-1 beta-Lactamase-producing Salmonella enterica Serovar Typhi, India.

Authors:  Bindiganavile N Gokul; Godfred A Menezes; Belgode N Harish
Journal:  Emerg Infect Dis       Date:  2010-07       Impact factor: 6.883

8.  Enteric Fever Caused by Salmonella enterica Serovars with Reduced Susceptibility of Fluoroquinolones at a Community Based Teaching Hospital of Nepal.

Authors:  Anjeela Bhetwal; Anjila Maharjan; Puspa Raj Khanal; Narayan Prasad Parajuli
Journal:  Int J Microbiol       Date:  2017-11-06

9.  Prevalence and antimicrobial resistance of Salmonella enterica subspecies enterica serovar Enteritidis isolated from broiler chickens in Shandong Province, China, 2013-2018.

Authors:  Xin Yu; Hongwei Zhu; Yongheng Bo; Youzhi Li; Yue Zhang; Yang Liu; Jianlong Zhang; Linlin Jiang; Guozhong Chen; Xingxiao Zhang
Journal:  Poult Sci       Date:  2020-10-28       Impact factor: 3.352

Review 10.  Green chemistry and coronavirus.

Authors:  Sepideh Ahmadi; Navid Rabiee; Yousef Fatahi; Seyyed Emad Hooshmand; Mojtaba Bagherzadeh; Mohammad Rabiee; Vahid Jajarmi; Rassoul Dinarvand; Sajjad Habibzadeh; Mohammad Reza Saeb; Rajender S Varma; Mohammadreza Shokouhimehr; Michael R Hamblin
Journal:  Sustain Chem Pharm       Date:  2021-03-03
View more
  1 in total

1.  gyrA ser83 mutation among fluoroquinolone-resistant Salmonella enterica serovars from enteric fever patients in tertiary care hospital, Kathmandu.

Authors:  Prashanna Adhikari; Roshani Maharjan; Subash Paudel; Bikram Malla; Pradeep Kumar Shah; Anup Bastola; Upendra Thapa Shrestha
Journal:  BMC Microbiol       Date:  2022-02-10       Impact factor: 3.605

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.